Search results for "embolism"

showing 10 items of 457 documents

Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards

2010

Abstract Introduction Current guidelines for ischemic stroke prevention in atrial fibrillation or flutter (AFF) recommend Vitamin K antagonists (VKAs) for patients at high-intermediate risk and aspirin for those at intermediate-low risk. The cost-effectiveness of these treatments was demonstrated also in elderly patients. However, there are several reports that emphasize the underuse of pharmacological prophylaxis of cardio-embolism in patients with AFF in different health care settings. Aims To evaluate the adherence to current guidelines on cardio-embolic prophylaxis in elderly (> 65 years old) patients admitted with an established diagnosis of AFF to the Italian internal medicine wards p…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaVitamin Kantithrombotic therapyNOAntithrombotic prophylaxis Atrial fibrillation Platelet agents Vitamin K antagonistsFibrinolytic AgentsRisk FactorsInternal medicineAntithromboticInternal MedicinemedicineHumansatrial fibrillationRegistriesMedical prescriptionStrokeAgedRetrospective StudiesAged 80 and overAntithrombotic prophylaxis; Atrial fibrillation; Platelet agents; Vitamin K antagonists;guidelines; antithrombotic therapy; atrial fibrillation.AspirinAspirinbusiness.industryantithrombotic prophylaxis; atrial fibrillation; platelet agents; vitamin k antagonistsAtrial fibrillationRetrospective cohort studyplatelet agentsmedicine.diseaseStrokevitamin k antagonistsIntracranial EmbolismItalyPlatelet aggregation inhibitorFemaleGuideline Adherenceantithrombotic prophylaxisbusinessguidelinePlatelet Aggregation InhibitorsFibrinolytic agentatrial fibrillation.medicine.drug
researchProduct

A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study

2015

Superficial vein thrombosis (SVT) is commonly encountered in clinical practice. Recent studies have suggested that the concomitant presence of deep vein thrombosis (DVT) or pulmonary embolism (PE) at the time of SVT diagnosis is not uncommon, thus increasing the interest on this disease. Whether this coexistence is predicted by specific risk factors remains unknown.To evaluate potential risk factors for DVT coexistence in patients presenting with acute objectively diagnosed SVT of the lower limbs and to develop a simple score entirely based on clinical variables to define the pre-test probability of DVT in these patients.A multicenter, retrospective cohort study on SVT patients was conducte…

Malemedicine.medical_specialtySuperficial vein thrombosisDeep veinCohort StudiesMedicinePulmonary embolism; Risk factors; Saphenous vein; Ultrasonography; Venous thrombosis;Humanscardiovascular diseasesUltrasonographyRetrospective StudiesVenous Thrombosisbusiness.industryPulmonary embolismRetrospective cohort studyHematologySaphenous veinPulmonary embolism; Risk factors; Saphenous vein; Ultrasonography; Venous thrombosis; Cohort Studies; Female; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Venous ThrombosisMiddle Agedmedicine.diseaseVenous thrombosiThrombosisPulmonary embolismVenous thrombosismedicine.anatomical_structureRisk factorsConcomitantFemaleRadiologyRisk factorbusinessCohort study
researchProduct

Usefulness of Clopidogrel Loading in Patients Who Underwent Transcatheter Aortic Valve Implantation (from the BRAVO-3 Randomized Trial)

2018

P2Y12-inhibitor initiation with clopidogrel using a loading dose (LD) versus no LD (NLD) provides more rapid inhibition of platelet activation and reduced risk of ischemic events after coronary stenting. Whether a similar beneficial effect is achieved in the setting of transcatheter aortic valve implantation (TAVI) is unknown. We evaluate the effects of preprocedural clopidogrel LD versus no NLD on 48-hour and 30-day clinical outcomes after TAVI. In the BRAVO-3 trial, 802 patients with severe aortic stenosis who underwent transfemoral TAVI were randomized to intraprocedural anticoagulation with bivalirudin or unfractionated heparin. Administration of clopidogrel LD was left to the discretio…

Malemedicine.medical_specialtyTime Factors030204 cardiovascular system & hematologyRisk AssessmentLoading doseTranscatheter Aortic Valve Replacement03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk FactorsThromboembolismInternal medicinePreoperative CaremedicineHumansBivalirudinProspective Studies030212 general & internal medicinePlatelet activationMyocardial infarction610 Medicine & healthProspective cohort studyStrokeAged 80 and overDose-Response Relationship Drugbusiness.industryIncidenceAortic Valve Stenosismedicine.diseaseClopidogrelClopidogrelEuropeStenosisNorth AmericaPurinergic P2Y Receptor AntagonistsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugThe American Journal of Cardiology
researchProduct

Efficacy and Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin in Atrial Fibrillation in Different Age Subgroups

2014

This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥75), and the overall population (All) from a US Medicare payer perspective. Clinical event rates by age cohort with dabigatran or warfarin for safety-on-treatment and intent-to-treat populations were estimated from Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY). An economic model was adapted using these data to evaluate the impact of starting age on clinical and economic outcomes. Costs were obtained from Medicare p…

Malemedicine.medical_specialtyTime FactorsCost effectivenessCost-Benefit AnalysisMedicareAntithrombinsDrug Administration ScheduleDrug CostsDabigatranThromboembolismInternal medicineAtrial FibrillationmedicineHumansIn patientcardiovascular diseasesStrokeAgedbusiness.industryIncidenceFollow up studiesWarfarinSystemic embolismAtrial fibrillationPrognosismedicine.diseaseUnited StatesDabigatranbeta-AlanineCardiologyBenzimidazolesFemalebusinessCardiology and Cardiovascular MedicineFollow-Up Studiesmedicine.drugThe American Journal of Cardiology
researchProduct

Quality of life and functional limitations after pulmonary embolism and its prognostic relevance

2019

Abstract Background While the importance of patients’ quality of life (QoL) in chronic cardiac or pulmonary disease is uncontroversial, the burden of an acute pulmonary embolism (PE) on QoL has received little attention thus far. Objectives We aimed to validate the German PEmb‐QoL questionnaire, identify associations between QoL and clinical/functional parameters, and investigate the prognostic relevance of QoL for long‐term survival in survivors of an acute PE episode. Patients/Methods Patients were invited for a clinical follow‐up visit including assessment of QoL using the German PEmb‐QoL questionnaire 6 months after an objectively confirmed PE at a single center. Internal consistency re…

Malemedicine.medical_specialtyTime FactorsPsychometricsPsychometricsHealth Status030204 cardiovascular system & hematologySingle Center03 medical and health sciences0302 clinical medicineCost of IllnessQuality of lifePredictive Value of TestsRisk FactorsInterquartile rangeGermanySurveys and QuestionnairesInternal medicinemedicineHumansProspective StudiesSurvivorsProspective cohort studyDepression (differential diagnoses)Agedbusiness.industryReproducibility of ResultsOriginal ArticlesHematologyMiddle AgedPrognosismedicine.diseasehumanities3. Good healthPulmonary embolismTHROMBOSISDyspneaPredictive value of testsQuality of LifeFemaleOriginal ArticleSymptom AssessmentPulmonary Embolismbusiness
researchProduct

Early extubation followed by immediate noninvasive ventilation vs. standard extubation in hypoxemic patients: a randomized clinical trial

2018

Purpose: Noninvasive ventilation (NIV) may facilitate withdrawal of invasive mechanical ventilation (i-MV) and shorten intensive care unit (ICU) length of stay (LOS) in hypercapnic patients, while data are lacking on hypoxemic patients. We aim to determine whether NIV after early extubation reduces the duration of i-MV and ICU LOS in patients recovering from hypoxemic acute respiratory failure. Methods: Highly selected non-hypercapnic hypoxemic patients were randomly assigned to receive NIV after early or standard extubation. Co-primary end points were duration of i-MV and ICU LOS. Secondary end points were treatment failure, severe events (hemorrhagic, septic, cardiac, renal or neurologic …

Malemedicine.medical_specialtyTime FactorsSedationmedicine.medical_treatmentWeaningAcute respiratory failureCritical Care and Intensive Care Medicinelaw.inventionHypoxemia03 medical and health sciences0302 clinical medicineTracheotomylawExtubationAnesthesiologymedicineHumansHypoxiaAgedMechanical ventilationChi-Square Distributionbusiness.industry030208 emergency & critical care medicineLength of StayMiddle Agedmedicine.diseaseIntensive care unitRespiration ArtificialPulmonary embolismIntensive Care Units030228 respiratory systemPneumothoraxItalyAnesthesiaBreathingAirway ExtubationFemalemedicine.symptomBlood Gas AnalysisbusinessVentilator WeaningNoninvasive ventilation
researchProduct

Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany.

2019

Abstract Aims Pulmonary embolism (PE) is the third most common cardiovascular cause of death; systemic thrombolysis is potentially lifesaving treatment in patients presenting with haemodynamic instability. We investigated trends in the use of systemic thrombolysis and the outcome of patients with acute PE. Methods and results We analysed data on the characteristics, comorbidities, treatment, and in-hospital outcome of 885 806 PE patients in Germany between 2005 and 2015. Incidence of acute PE was 99/100 000 population/year and increased from 85/100 000 in 2005 to 109/100 000 in 2015 [β 0.32 (0.26–0.38), P &amp;lt; 0.001]. During the same period, in-hospital case fatality rates decreased fro…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulation030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsInternal medicineGermanyCase fatality ratemedicineHumansThrombolytic TherapyCardiopulmonary resuscitationHospital MortalityeducationCause of deathAgedRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industryMortality rate030229 sport sciencesThrombolysisMiddle Agedmedicine.diseasePulmonary embolismTreatment OutcomeAcute DiseaseCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPulmonary EmbolismFibrinolytic agentFollow-Up StudiesEuropean heart journal
researchProduct

Handgrip strength is not associated with risk of venous thromboembolism: a prospective cohort study.

2020

Objectives. Consistent evidence suggests an inverse and independent association between handgrip strength and arterial thrombotic disease. However, whether handgrip strength is related to future risk of venous thromboembolism (VTE) is uncertain. We sought to assess the prospective association between handgrip strength and VTE risk. Design. Handgrip strength was assessed using a hand dynamometer in a population-based sample of 864 men and women aged 61–74 years without a history of VTE at baseline in the Kuopio Ischemic Heart Disease prospective cohort study. Handgrip strength was allometrically scaled to account for the effect of body weight (handgrip strength/body weight2/3) and to normali…

Malemedicine.medical_specialtyTime Factorsvenous thromboembolism030204 cardiovascular system & hematologyHandgrip strengthRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinecohort studymedicineHumansThrombotic disease030212 general & internal medicineProspective StudiesProspective cohort studyFinlandAgedHand Strengthbusiness.industrymusculoskeletal neural and ocular physiologyAge FactorsVenous ThromboembolismMiddle AgedPrognosisbody regionscardiovascular systemFemaleCardiology and Cardiovascular Medicinebusinesshuman activitiesVenous thromboembolismcirculatory and respiratory physiologyCohort studyScandinavian cardiovascular journal : SCJ
researchProduct

Pulmonary embolism: risk assessment and management.

2012

Acute pulmonary embolism (PE) poses a significant burden on health and survival. Its severity ranges from asymptomatic, incidentally discovered subsegmental thrombi to massive, pressor-dependent PE complicated by cardiogenic shock and multisystem organ failure. Rapid and accurate risk stratification is therefore of paramount importance to ensure the highest quality of care. This article critically reviews currently available and emerging tools for risk-stratifying acute PE, and particularly for distinguishing between elevated (intermediate) and low risk among normotensive patients. We focus on the potential value of risk assessment strategies for optimizing severity-adjusted management. Apa…

Malemedicine.medical_specialtyVena Cava FiltersVitamin Kmedicine.medical_treatmentEarly TherapyRisk AssessmentSeverity of Illness IndexRecurrenceSeverity of illnessmedicineAmbulatory CareHumansThrombolytic TherapyIntensive care medicineAgedRandomized Controlled Trials as TopicThrombectomybusiness.industryHeparinCardiogenic shockAnticoagulantsThrombolysisLength of StayMiddle Agedmedicine.diseasePrognosisPulmonary embolismCardiac Imaging TechniquesEmbolismAcute DiseaseFemaleCardiology and Cardiovascular MedicineMultiple organ dysfunction syndromeRisk assessmentbusinessPulmonary EmbolismBiomarkersEuropean heart journal
researchProduct

D-Dimer and thrombus burden in acute pulmonary embolism.

2018

Abstract Background Thrombus burden in pulmonary embolism (PE) is associated with higher D-Dimer-levels and poorer prognosis. We aimed to investigate i) the influence of right ventricular dysfunction (RVD), deep venous thrombosis (DVT), and high-risk PE-status on D-Dimer-levels and ii) effectiveness of D-Dimer to predict RVD in normotensive PE patients. Methods Overall, 161 PE patients were analyzed retrospectively, classified in 5 subgroups of thrombus burden according to clinical indications and compared regarding D-Dimer-levels. Linear regression models were computed to investigate the association between D-Dimer and the groups. In hemodynamically stable PE patients, a ROC curve was calc…

Malemedicine.medical_specialtyVentricular Dysfunction Right030204 cardiovascular system & hematologyLogistic regressionFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineD-dimerLinear regressionmedicineHumans030212 general & internal medicineAgedRetrospective StudiesVenous Thrombosisbusiness.industryCancerGeneral Medicinemedicine.diseasePrognosisPulmonary embolismVenous thrombosisPneumoniaROC CurveThrombus burdenAcute DiseaseEmergency MedicineCardiologyFemalebusinessPulmonary EmbolismBiomarkersThe American journal of emergency medicine
researchProduct